Geron Corporation
GERNGeron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
GERN Earnings Report
EPS Est: $-0.01 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How GERN's past catalysts played out
Imetelstat
Myelofibrosis
Imetelstat sodium
Locally Recurrent or Metastatic Breast Cancer
Imetelstat 4.7 mg/kg
Myelofibrosis
Imetelstat (7.5 mg/kg)
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Imetelstat | Phase 3 | Myelofibrosis | - | - |
Imetelstat sodium | Phase 3 | Locally Recurrent or Metastatic Breast Cancer | - | - |
Imetelstat 4.7 mg/kg | Phase 2 | Myelofibrosis | - | - |
Imetelstat (7.5 mg/kg) | Phase 2 | Multiple Myeloma | - | - |
Myelofibrosis
2 drugs in this indication
Multiple Myeloma
1 drug in this indication
Locally Recurrent or Metastatic Breast Cancer
1 drug in this indication
Non-small Cell Lung Cancer
1 drug in this indication
Myelodysplastic Syndromes
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Geron Corporation's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Geron Corporation's (GERN) pipeline across Phase 3, Phase 2. Its lead program is Imetelstat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Geron Corporation's next FDA catalyst?→
Geron Corporation's (GERN) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GERN biotech catalysts?→
Add GERN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Geron Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.